The aim of this study is to assess the concentration of soluble forms of L1CAM in sera of patients with endometrial and ovarian cancer and verify the feasibility of sL1CAM as a marker of the disease and its correlation with clinicopathological parameters of the disease. The gene discussed is L1CAM; the disease is ovarian carcinoma.